Citations

Mayo Clinic

Showing 10 of 108551 citations.

High-Density Glass Scintillators for Proton Radiography—Relative Luminosity, Proton Response, and Spatial Resolution
Stolen, Ethan , Fullarton, Ryan , Hein, Rain, Conner, Robin L., Jacobsohn, Luiz G. , Collins‐Fekete, Charles‐Antoine , Beddar, Sam , Akgun, U. , Robertson, Daniel , Akgun, Ugur

Sensors | March 27, 2024 | Volume: 24 | Issue: 7 | Pages: 2137

10.3390/s24072137 | PMID 38610351 Get It

Proton radiography is a promising development in proton therapy, and researchers are currently exploring optimal detector materials to construct proton radiography detector arrays. High-density glass scintillators may improve integrating-mode proton radiography detectors by increasing spatial resolution and decreasing detector thickness. We evaluated several new scintillators, activated with europium or terbium, with proton response measurements and Monte Carlo simulations, characterizing relative luminosity, ionization quenching, and proton radiograph spatial resolution. We applied a correction based on Birks’s analytical model for ionization quenching. The data demonstrate increased relative luminosity with increased activation element concentration, and higher relative luminosity for samples activated with europium. An increased glass density enables more compact detector geometries and higher spatial resolution. These findings suggest that a tungsten and gadolinium oxide-based glass activated with 4% europium is an ideal scintillator for testing in a full-size proton radiography detector.
New-Onset Diabetes Mellitus after Kidney Transplantation
Alajous, Salah, Budhiraja, Pooja , Budhiraja, Pooja

Journal of Clinical Medicine | March 27, 2024 | Volume: 13 | Issue: 7 | Pages: 1928

10.3390/jcm13071928 | PMID 38610694 Get It

New-Onset Diabetes Mellitus after Transplantation (NODAT) emerges as a prevalent complication post-kidney transplantation, with its incidence influenced by variations in NODAT definitions and follow-up periods. The condition’s pathophysiology is marked by impaired insulin sensitivity and β-cell dysfunction. Significant risk factors encompass age, gender, obesity, and genetics, among others, with the use of post-transplant immunosuppressants intensifying the condition. NODAT’s significant impact on patient survival and graft durability underscores the need for its prevention, early detection, and treatment. This review addresses the complexities of managing NODAT, including the challenges posed by various immunosuppressive regimens crucial for transplant success yet harmful to glucose metabolism. It discusses management strategies involving adjustments in immunosuppressive protocols, lifestyle modifications, and pharmacological interventions to minimize diabetes risk while maintaining transplant longevity. The importance of early detection and proactive, personalized intervention strategies to modify NODAT’s trajectory is also emphasized, advocating for a shift towards more anticipatory post-transplant care.
Impact of Thrombocytopenia on Survival in Patients with Hepatocellular Carcinoma: Updated Meta-Analysis and Systematic Review
Kraj, Leszek , Chmiel, Paulina , Gryziak, Maciej, Grabowska-Derlatka, Laretta , Szymański, Łukasz , Wysokińska, Ewa, Szymański, Łukasz

Cancers | March 27, 2024 | Volume: 16 | Issue: 7 | Pages: 1293

10.3390/cancers16071293 | PMID 38610973 Get It

Background: Platelets (PLT) have a role in the pathogenesis, progression, and prognosis of hepatocellular carcinoma (HCC) and could represent a readily measurable laboratory parameter to enhance the comprehensive evaluation of HCC patients. Methods: The PubMed, Web of Science, and Scopus databases were searched with a focus on survival as well as patient and tumor-specific characteristics in correlation to reported PLT counts. Survival outcomes were analyzed with both common-effect and random-effects models. The hazard ratio (HR) and its 95% confidence interval (CI) from analyzed trials were incorporated. Studies that did not provide survival data but focused on platelet count correlation with HCC characteristics were reviewed. Results: In total, 26 studies, including a total of 9403 patients, met our criteria. The results showed that thrombocytopenia in HCC patients was associated with poor overall survival (common-effect HR = 1.15, 95% CI: 1.06–1.25; random-effect HR = 1.30, 95% CI: 1.05–1.63). Moreover, three studies reveal significant correlations between PLT indices and tumor characteristics such as size, foci number, and etiology of HCC development. Conclusion: Our meta-analysis confirmed that PLT count could act as a prognostic marker in HCC, especially with a PLT count cut off <100 × 103/mm3. Further prospective studies focusing on the role of PLT in clearly defined subgroups are necessary.
Trends and Disparities in Cardiovascular Death in Sarcoidosis: A Population‐Based Retrospective Study in the United States From 1999 to 2020
Tan, Min Choon , Yeo, Yong Hao , Mirza, Noreen , San, Boon Jian , Tan, Jian Liang , Lee, Justin Z. , Mazzarelli, Joanne K. , Russo, Andrea M. , Yeo, Yong Hao , Tan, Min C

Journal of the American Heart Association | March 27, 2024 | Volume: 13 | Issue: 7 | Pages: No page available

10.1161/jaha.123.031484 | PMID 38533928 Get It

Background Despite significant cardiac involvement in sarcoidosis, real‐world data on death due to cardiovascular disease among patients with sarcoidosis is not well established. Methods and Results We queried the Centers for Disease Control and Prevention's Wide‐Ranging Online Data for Epidemiologic Research database for data on patients with sarcoidosis aged ≥25 years from 1999 to 2020. Diseases of the circulatory system except ischemic heart disease were listed as the underlying cause of death, and sarcoidosis was stated as a contributing cause of death. We calculated age‐adjusted mortality rate (AAMR) per 1 million individuals and determined the trends over time by estimating the annual percentage change using the Joinpoint Regression Program. Subgroup analyses were performed on the basis of demographic and geographic factors. In the 22‐year study period, 3301 cardiovascular deaths with comorbid sarcoidosis were identified. The AAMR from cardiovascular deaths with comorbid sarcoidosis increased from 0.53 (95% CI, 0.43–0.65) per 1 million individuals in 1999 to 0.87 (95% CI, 0.75–0.98) per 1 million individuals in 2020. Overall, women recorded a higher AAMR compared with men (0.77 [95% CI, 0.74–0.81] versus 0.58 [95% CI, 0.55–0.62]). People with Black ancestry had higher AAMR than people with White ancestry (3.23 [95% CI, 3.07–3.39] versus 0.39 [95% CI, 0.37–0.41]). A higher percentage of death was seen in the age groups of 55 to 64 years in men (23.11%) and women (21.81%), respectively. In terms of US census regions, the South region has the highest AAMR from cardiovascular deaths with comorbid sarcoidosis compared with other regions (0.78 [95% CI, 0.74–0.82]). Conclusions The increase of AAMR from cardiovascular deaths with comorbid sarcoidosis and higher cardiovascular mortality rates among adults aged 55 to 64 years highlight the importance of early screening for cardiovascular diseases among patients with sarcoidosis.
Trends and Disparities Around Cardiovascular Mortality in Sarcoidosis: Does Big Data Have the Answers?
Ahmed, Raheel , Sharma, Rakesh , Chahal, C. Anwar A. , Chahal, Choudhary Anwar A , Ahmed, Raheel , Sharma, Rakesh

Journal of the American Heart Association | March 27, 2024 | Volume: 13 | Issue: 7 | Pages: No page available

10.1161/jaha.124.034073 | PMID 38533935 Get It

Case study of invalid to valid shift in cognitive performance following successful treatment of psychogenic nonepileptic seizure events
Drane, Daniel L. , Price, Michele E., Rush, Beth K., Blackmon, Karen , Okada, Noah , Shade, Taylor, Valentin, Edward, Vinson, Joseph, Rosen, Phyllis, Hewitt, Kelsey C. , Valentin, Edward, Loring, David W.

Journal of Clinical and Experimental Neuropsychology | March 27, 2024 | Volume: 45 | Issue: 10 | Pages: 1024-1038

10.1080/13803395.2024.2335600 | PMID 38533868 Get It

Sleep disturbances in chronic liver disease
Busebee, Bradley , Watt, Kymberly D. , Dupuy-McCauley, Kara , DuBrock, Hilary, Busebee, Brad , DuBrock, Hilary M.

Liver Transplantation | March 27, 2024 | Volume: 30 | Issue: 10 | Pages: 1058-1071

10.1097/lvt.0000000000000369 | PMID 38535627 Get It

Sleep disturbances are common in chronic liver disease and significantly impact patient outcomes and quality of life. The severity and nature of sleep disturbances vary by liver disease etiology and severity. While there is ongoing research into the association between liver disease and sleep-wake dysfunction, the underlying pathophysiology varies and, in many cases, is poorly understood. Liver disease is associated with alterations in thermoregulation, inflammation, and physical activity, and is associated with disease-specific complications, such as HE, that may directly affect sleep. In this article, we review the relevant pathophysiologic processes, disease-specific sleep-wake disturbances, and clinical management of CLD-associated sleep-wake disturbances.
Interest of rare autoantibodies in autoimmune encephalitis and paraneoplastic neurological syndromes: the utility (or futility) of rare antibody discovery
Segal‬‏, Yahel , Ζεκερίδου, Αναστασία , Segal, Yahel

Current Opinion in Neurology | March 27, 2024 | Volume: 37 | Issue: 3 | Pages: 295-304

10.1097/wco.0000000000001261 | PMID 38533672 Get It

Purpose of review The increasing recognition and diagnosis of autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) is partly due to neural autoantibody testing and discovery. The past two decades witnessed an exponential growth in the number of identified neural antibodies. This review aims to summarize recent rare antibody discoveries in the context of central nervous system (CNS) autoimmunity and evaluate the ongoing debate about their utility. Recent findings In the last 5 years alone 15 novel neural autoantibody specificities were identified. These include rare neural antibody biomarkers of autoimmune encephalitis, cerebellar ataxia or other movement disorders, including multifocal presentations. Summary Although the clinical applications of these rare antibody discoveries may be limited by the low number of positive cases, they still provide important diagnostic, prognostic, and therapeutic insights.
The utility of electrodiagnostic testing in unprovoked rhabdomyolysis in the era of next‐generation sequencing
Skolka, Michael , Milone, Margherita , Litchy, William J. , Laughlin, Ruple S. , Rubin, Devon I., Skolka, Michael P., Liewluck, T , Skolka, Michael P , Liewluck, Teerin

Muscle & Nerve | March 27, 2024 | Volume: 70 | Issue: 2 | Pages: 180-186

10.1002/mus.28087 | PMID 38533679 Get It

AbstractIntroduction/AimsRhabdomyolysis is an etiologically heterogeneous, acute necrosis of myofibers characterized by transient marked creatine kinase (CK) elevation associated with myalgia, muscle edema, and/or weakness. The study aimed to determine the role of electrodiagnostic (EDX) testing relative to genetic testing and muscle biopsy in patients with unprovoked rhabdomyolysis in identifying an underlying myopathy.MethodsEDX database was reviewed to identify unprovoked rhabdomyolysis patients who underwent EDX testing between January 2012 and January 2022. Each patient's clinical profile, EDX findings, muscle pathology, laboratory, and genetic testing results were analyzed.ResultsOf 66 patients identified, 32 had myopathic electromyography (EMG). Muscle biopsy and genetic testing were performed in 41 and 37 patients, respectively. A definitive diagnosis was achieved in 15 patients (11 myopathic EMG and 4 nonmyopathic EMG; p = .04) based on abnormal muscle biopsy (4/11 patients) or genetic testing (12/12 patients, encompassing 5 patients with normal muscle biopsy and 3 patients with nonmyopathic EMG). These included seven metabolic and eight nonmetabolic myopathies (five muscular dystrophies and three ryanodine receptor 1 [RYR1]‐myopathies). Patients were more likely to have baseline weakness (p < .01), elevated baseline CK (p < .01), and nonmetabolic myopathies (p = .03) when myopathic EMG was identified.DiscussionMyopathic EMG occurred in approximately half of patients with unprovoked rhabdomyolysis, more likely in patients with weakness and elevated CK at baseline. Although patients with myopathic EMG were more likely to have nonmetabolic myopathies, nonmyopathic EMG did not exclude myopathy, and genetic testing was primarily helpful to identify an underlying myopathy. Genetic testing should likely be first‐tier diagnostic testing following unprovoked rhabdomyolysis.
Patient Access of Their Radiology Reports Before and After Implementation of 21st Century Cures Act Information-Blocking Provisions at a Large Multicampus Health System
Petty, Skye A. Buckner, Schmitz, John J. , Varner, Jacob, Metcalfe, Allie M., Pollock, Jordan Riley , Tan, Nelly

American Journal of Roentgenology | March 27, 2024 | Volume: 222 | Issue: 6 | Pages: No page available

10.2214/ajr.23.30343 | PMID 38534191 Get It